VWF and hepatocellular carcinoma: Our finding was in concordance with the previous identification of sEV–vWF as a potential biomarker of HCC using a data‐independent acquisition method.[16] The upregulation of sEV–vWF in HCC patients was further validated in an independent cohort of 101 samples comprising circulating sEVs obtained from control subjects without liver diseases and patients with chronic hepatitis B virus infection, cirrhosis, and HCC at early and advanced stages.